DDIF 2027 · Who attends
Senior delegates
150
Invited organisations
30
Days · The Savoy
2
Curated sessions
14
The disciplines
Discovery leadership
Chief Scientific Officers, Head of Drug Discovery, R&D Portfolio leads
CMC leadership
VP and SVP CMC, Head of Process Development, Global Biologics Operations
Regulatory strategy
Global Regulatory Affairs leads, Submission Directors, RA VPs
Clinical operations
Phase I to III Programme Directors, CMO and Medical Directors
Commercial development
BD leads, Licensing heads, Portfolio Strategy Directors
Enabling technology
Informatics, AI/ML in drug discovery, digital research platforms
DDIF 2027 · Invited audience
AstraZeneca
GSK
Roche
Novartis
Sanofi
Bayer
Boehringer Ingelheim
Merck KGaA
Novo Nordisk
Lundbeck
UCB
Galapagos
Argenx
BioNTech
Evotec
Pfizer
Eli Lilly
Merck & Co.
J&J
Bristol Myers Squibb
AbbVie
Gilead
Amgen
Vertex
Regeneron
Moderna
Genentech
Takeda
Daiichi Sankyo
Astellas
Audience confirmed at prospectus stage. Subject to annual review.
A note on privacy.
This site uses essential cookies to function. We optionally use analytics to understand how the site is used. Nothing is shared. Nothing is sold.